BANNER HEALTH | MedPath

Alamar Biosciences Revolutionizes Alzheimer's Detection with Blood-Based Brain-Derived Tau Assays

7 days ago

• Alamar Biosciences has expanded its NULISAseq CNS Disease Panel 120 with first-of-its-kind blood-based assays that can specifically detect brain-derived phosphorylated tau proteins, a critical biomarker for Alzheimer's disease. • The enhanced panel overcomes previous limitations by distinguishing between peripheral and central tau species, allowing simultaneous measurement of brain-derived pTau217, pTau181, pTau231, and total tau directly from blood samples. • Experts believe this advancement will transform early detection and monitoring of neurodegenerative diseases, potentially accelerating biomarker-driven research and improving diagnostic accuracy for Alzheimer's disease.

Hilo Secures $42 Million Series B Funding to Revolutionize Blood Pressure Monitoring

14 days ago

• Hilo (formerly Aktiia) has raised $42 million in Series B funding to advance its cuffless blood pressure monitoring technology, bringing total financing to over $100 million. • The funding round was co-led by Earlybird Health and Wellington Partners, with participation from new investors Kfund and naturalX Health Ventures, alongside existing investors including Khosla Ventures. • With 120,000 devices sold and regulatory approvals in multiple countries, Hilo aims to address the global hypertension crisis where only 20% of affected individuals have their blood pressure under control.

nference and BeiGene Partner on AI-Driven Research to Advance B-Cell Cancer Treatment

a month ago

• nference and BeiGene have launched a collaboration leveraging AI technology to analyze treatment patterns for chronic lymphocytic leukemia and small lymphocytic lymphoma from real-world data. • The retrospective study will examine over 700 patient charts using nference's proprietary Agentic AI platform to identify treatment patterns and improve clinical decision-making for B-cell malignancies. • This partnership aims to generate comprehensive real-world evidence that could lead to more personalized and effective care options for patients with CLL, which is the most common adult leukemia in the United States.

Top Healthcare Experts Share Insights on Obesity Management, Primary Care Innovation, and Health Equity in 2024 IVBM Coverage

5 months ago

• The Institute for Value-Based Medicine's top coverage in 2024 highlighted critical developments in obesity treatment, including discussions on GLP-1 agonists and multidisciplinary care approaches. • Healthcare leaders emphasized the urgent need for primary care innovation, addressing workforce shortages and implementing AI-driven solutions to enhance care delivery and efficiency. • Experts across multiple institutions stressed the importance of addressing social determinants of health and health inequities in primary care, while advocating for improved metabolic health measurements in obesity care.

Alzheimer's Patient Finds Hope and Purpose Through Clinical Trial Participation

6 months ago

• Bob Ehlers, diagnosed with mild cognitive impairment from Alzheimer's, participates in a clinical trial at Banner Alzheimer's Institute to combat disease progression. • Ehlers highlights the benefits of clinical trial participation, including access to cutting-edge treatments and comprehensive support, such as transportation and meals. • His involvement in trials contributed to the FDA approval of lecanemab, providing him with a sense of accomplishment and contribution to Alzheimer's treatment. • Beyond clinical trials, Ehlers actively engages in advocacy and volunteer work, supporting others with memory loss and promoting cognitive engagement.

FDA Approves Supernus' ONAPGO for Motor Fluctuations in Advanced Parkinson's Disease

6 months ago

• The FDA has approved ONAPGO (apomorphine hydrochloride) as the first subcutaneous apomorphine infusion device for treating motor fluctuations in advanced Parkinson's disease. • ONAPGO, a wearable device, provides continuous subcutaneous apomorphine infusion, offering more consistent control of OFF time for Parkinson's patients. • Clinical trials demonstrated that ONAPGO significantly reduced daily OFF time by 2.6 hours compared to placebo, with improvements seen as early as week 1. • Supernus plans to launch ONAPGO in the U.S. in the second quarter of 2025, supported by a dedicated nurse education program and access support.

Ivy Brain Tumor Center Launches Clinical Trial for Brain Cancer Treatment

9 months ago

• The Ivy Brain Tumor Center in Phoenix is conducting a clinical trial to evaluate a new drug for treating brain cancer patients. • The trial marks a significant step in exploring innovative therapies for extending the lives of individuals diagnosed with brain tumors. • The first patient in the clinical trial is from Arizona, highlighting the center's commitment to local healthcare advancements.